Linda R Mileshkin

14PUBLICATIONS
124CO-AUTHORS
Predictive and prognostic markersHaematological tumoursCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)Epidemiological modelling
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Sep 03, 2026
Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study.

|Jul 08, 2026
Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.

|May 20, 2025
Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primary.

Richard J Rebello, Atara Posner, Ruining Dong

|Nov 14, 2024
Unravelling mutational signatures with plasma circulating tumour DNA.

Sebastian Hollizeck, Ning Wang, Stephen Q Wong

|Oct 21, 2024
Impact of chemotherapy on patients with mismatch repair deficient advanced endometrial carcinomas-a meta-analysis.

Angelina Tjokrowidjaja, Peey-Sei Kok, Yoland C Antill

|Oct 07, 2024
Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2-Low.

Dione van Dijk, Lisa Vermij, Alicia León-Castillo

Pageof 3

Frequent Collaborators

3 joint publications

Tjalling Bosse

3 joint publications

Nanda Horeweg

3 joint publications

Richard W Tothill

2 joint publications

Jeffrey S Ross